This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    GTI1305
Previous Study | Return to List | Next Study

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Grifols Therapeutics Inc.
Sponsor:
Information provided by (Responsible Party):
Grifols Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT02413580
First received: April 7, 2015
Last updated: August 2, 2017
Last verified: August 2017
  Purpose
This is a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.

Condition Intervention Phase
Myasthenic Crisis Biological: IGIV-C Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations

Resource links provided by NLM:


Further study details as provided by Grifols Therapeutics Inc.:

Primary Outcome Measures:
  • Change in quantitative myasthenia gravis (QMG) scale score [ Time Frame: From Baseline (Day 0) to Day 14 ]

Secondary Outcome Measures:
  • Percentage of subjects with clinical improvement assessed by QMG [ Time Frame: Baseline (Day 0) to Day 14 ]
  • Percentage of subjects with clinical improvement assessed by MG-Activities of Daily Living (MG-ADL) [ Time Frame: Baseline (Day 0) to Day 14 ]
  • Percentage of subjects with clinical improvement assessed by the MG Composite [ Time Frame: Baseline (Day 0) to Day 14 ]

Estimated Enrollment: 50
Study Start Date: March 2015
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IGIV-C Treatment
An IV dose of 2 g/kg of IGIV-C will be administered in subjects with myasthenia gravis exacerbations.
Biological: IGIV-C
an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days

Detailed Description:
The study consists of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject is up to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, are planned to be enrolled in the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe and South Africa.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be willing and able to provide written informed consent (if applicable, a legally authorized representative may provide informed consent on behalf of the subject).
  • Subjects who meet the clinical criteria for diagnosis of MG with an exacerbation defined as worsening of MG symptoms as defined by an Myasthenia Gravis Foundation of America (MGFA) classification IVb or V.
  • Subjects on long-term (8 weeks) corticosteroid treatment for MG.
  • Female subjects of child-bearing potential must have a negative test for pregnancy (human chorionic gonadotropin [HCG-based assay]).
  • Subjects must be willing to comply with all aspects of the clinical trial protocol, including blood sampling and long-term storage of extra samples, for the entire duration of the study.

Exclusion Criteria:

  • Subjects who have received immune globulin treatment given by IV, subcutaneous or intramuscular route within the last 30 days.
  • Subjects with documentation of a lack of clinical response to intravenous immunoglobulin (IVIg) therapy for MG.
  • Subjects documented positive for antibodies directed against MuSK.
  • Subjects with corticosteroid (CS) treatment initiated within the last 8 weeks or modified within the last 2 weeks.
  • Subjects with plasma exchange (PLEX) within the last 30 days.
  • Subjects with MG exacerbation attributable to change in medication or infection or evident infection as defined by, but not limited to, the presence of at least one of the following diagnostic features: 1) axillary temperature ≥38°C, 2) positive blood culture of infective microorganism, 3) white blood cell count >12×10^9/L and differential white blood cell count of >10% band neutrophils (>1.2×10^9/L), and 4) pulmonary infiltrate with consolidation on chest X-ray. Alternatively, other signs and symptoms may be considered for the diagnosis of evident infection according to the Investigator's judgement.
  • Subjects with inadequate venous access.
  • Subjects with a history of anaphylactic reactions or severe reactions to any blood-derived product.
  • Subjects with a history of intolerance to any component of the investigational products.
  • Subjects with a documented diagnosis of thrombotic complications to polyclonal IVIG therapy in the past.
  • Subjects with a history of recent (within the last year) myocardial infarction, stroke or uncontrolled hypertension.
  • Subjects who suffer from uncontrolled congestive heart failure, embolism or documented electrocardiogram (ECG) changes indicative of myocardial ischemia or atrial fibrillation.
  • Subjects with current known hyperviscosity or hypercoagulable state.
  • Subjects currently receiving anti-coagulation therapy.
  • Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the 12 months preceding the Baseline Visit.
  • Subjects currently receiving, or having received within 3 months prior to the Baseline Visit, any investigational medicinal product or device.
  • Subjects with a known Immunoglobulin A (IgA) deficiency and anti-IgA serum antibodies.
  • Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 times the upper limit of normal [ULN] for the expected normal range for the testing laboratory).
  • Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceeding more than 2.5 times the ULN for the expected normal range for the testing laboratory.
  • Subjects with haemoglobin levels <9 g/dL.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02413580

Contacts
Contact: Sandra Camprubi, PhD sandra.camprubi@grifols.com

  Show 33 Study Locations
Sponsors and Collaborators
Grifols Therapeutics Inc.
  More Information

Responsible Party: Grifols Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02413580     History of Changes
Other Study ID Numbers: GTI1305
Study First Received: April 7, 2015
Last Updated: August 2, 2017

Additional relevant MeSH terms:
Myasthenia Gravis
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on August 18, 2017